MedTrace Logo

Glofitamab in Real Life

NCT06994169 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 250

Last updated 2026-01-14

No results posted yet for this study

Summary

To date, more than 300 patients have been treated with Glofitamab in the Expanded Access Programme (EAP) in France. In this study, it is proposed to perform a retrospective analysis of some of these patients. The aim is to describe the efficacy and safety of Glofitamab in the largest reported real-world cohort, with an expected median follow-up of more than 9 months. Particular focus will be given to the relapsed or refractory chimeric antigen receptors-T (CAR-T) population to confirm the response rates (CRR: 35-39%) of Glofitamab in this population and to assess the optimal timing of therapy initiation \[8, 15\].

Conditions

Interventions

DRUG

Glofitamab

Glofitamab received for DLBCL in Early Phase Access

Sponsors & Collaborators

  • The Lymphoma Academic Research Organisation

    lead OTHER

Principal Investigators

  • Guillaume MANSON, MD · Lymphoma Study Association

  • Gilles CROCHET, MD · The Lymphoma Academic Research Organisation

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-12-01
Primary Completion
2026-03-30
Completion
2026-07-30

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06994169 on ClinicalTrials.gov